Foghorn Therapeutics Inc Quick Ratio (FHTX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Foghorn Therapeutics Inc   (NASDAQ: FHTX)

Foghorn Therapeutics Inc 's Quick Ratio

FHTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Foghorn Therapeutics Inc 's Cash & cash equivalent, this led to improvement in Foghorn Therapeutics Inc 's Quick Ratio to 3.31, Quick Ratio remained below Foghorn Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 228 other companies have achieved higher Quick Ratio than Foghorn Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 1168, from total ranking in the first quarter 2026 at 1454.

Explain Quick Ratio?
How much Cash & cash equivalents FHTX´s has?
What are FHTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

FHTX Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -34.98 % -9.68 % -10.82 % 49.74 % 52.91 %
Y / Y Cash & cash equivalent Change -15.65 % -16.75 % -34.81 % -32.58 % -30.34 %
Quick Ratio MRQ 3.31 2.85 2.66 2.12 2.55
FHTX's Total Ranking # 1168 # 1454 # 1511 # 1397 # 1264
Seq. Current Liabilities Change -21.47 % 7.81 % -29.79 % 9.39 % 9.08 %
Seq. Cash & cash equivalent Change -8.74 % 15.57 % -11.86 % -9.26 % -9.94 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 229
Healthcare Sector # 386
Overall Market # 1046


Quick Ratio Statistics
High Average Low
14.47 5.27 1.33
(Dec 31 2020)   (Dec 31 2019)




Financial Statements
Foghorn Therapeutics Inc 's Current Liabilities $ 51 Millions Visit FHTX's Balance sheet
Foghorn Therapeutics Inc 's Cash & cash equivalent $ 168 Millions Visit FHTX's Balance sheet
Source of FHTX's Sales Visit FHTX's Sales by Geography


Cumulative Foghorn Therapeutics Inc 's Quick Ratio

FHTX's Quick Ratio for the trailling 12 Months

FHTX Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -4.8 % 16.68 % 29.62 % 38.03 % 27.9 %
Y / Y Cash & cash equivalent TTM Growth -25.8 % -29.05 % -24.38 % -15.1 % -5.62 %
Quick Ratio TTM 2.66 2.51 2.58 2.8 3.41
Total Ranking TTM # 1159 # 1446 # 1181 # 1221 # 963
Seq. Current Liabilities TTM Growth -9.48 % -2.35 % -2.41 % 10.36 % 10.94 %
Seq. Cash & cash equivalent TTM Growth -4.31 % -4.87 % -10.06 % -9.36 % -8.51 %

Quick ratio ranking by company, industry and sector >> Back to FHTX Financial Strength Comparisons >> Go to Compare FHTX Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Foghorn Therapeutics Inc 's average Cash & cash equivalent, this led to increase in in Foghorn Therapeutics Inc 's Quick Ratio to 2.66, above FHTX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 433 other companies have achieved higher Quick Ratio than Foghorn Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3722.

Explain Quick Ratio?
How much Cash & cash equivalents FHTX´s has?
What are FHTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 434
Healthcare Sector # 888
Within the Market # 1168


trailing twelve months Quick Ratio Statistics
High Average Low
7.72 2.15 0.9
(Jun 30 2021)   (Jun 30 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Marker Therapeutics inc   9.10 $ 22.031  Millions$ 2.420  Millions
Synlogic Inc   9.03 $ 13.200  Millions$ 1.461  Millions
Spruce Biosciences Inc   8.78 $ 96.300  Millions$ 10.963  Millions
Newamsterdam Pharma Company N v   8.69 $ 633.854  Millions$ 72.974  Millions
Medicinova Inc   8.58 $ 25.416  Millions$ 2.961  Millions
Lixte Biotechnology Holdings Inc   8.45 $ 12.670  Millions$ 1.500  Millions
Atrium Therapeutics Inc   8.38 $ 264.135  Millions$ 31.508  Millions
Cytomx Therapeutics Inc   8.29 $ 330.280  Millions$ 39.861  Millions
Grace Therapeutics Inc  8.24 $ 13.756  Millions$ 1.669  Millions
Talphera Inc   7.98 $ 33.410  Millions$ 4.188  Millions
Rocket Pharmaceuticals Inc   7.79 $ 342.940  Millions$ 44.031  Millions
Milestone Pharmaceuticals Inc   7.73 $ 171.481  Millions$ 22.184  Millions
Nuvation Bio Inc   7.62 $ 660.956  Millions$ 86.755  Millions
Ibio inc   7.50 $ 88.049  Millions$ 11.745  Millions
Promis Neurosciences inc   7.41 $ 53.463  Millions$ 7.218  Millions
Lakewood-Amedex Biotherapeutics Inc.  7.29 $ 4.585  Millions$ 0.629  Millions
Aspire Biopharma Holdings Inc   7.22 $ 12.167  Millions$ 1.686  Millions
Cartesian Therapeutics Inc   7.18 $ 147.606  Millions$ 20.550  Millions
Kiora Pharmaceuticals Inc   7.10 $ 16.839  Millions$ 2.370  Millions
Arvinas Inc   6.88 $ 567.900  Millions$ 82.500  Millions
Summit Therapeutics Inc   6.67 $ 690.749  Millions$ 103.566  Millions
Alumis inc   6.59 $ 502.300  Millions$ 76.233  Millions
Novelos Therapeutics, Inc.  6.49 $ 33.994  Millions$ 5.238  Millions
Genprex Inc   6.47 $ 15.154  Millions$ 2.342  Millions
Lisata Therapeutics Inc   6.45 $ 19.277  Millions$ 2.987  Millions
Larimar Therapeutics Inc   6.44 $ 219.880  Millions$ 34.166  Millions
United Therapeutics Corporation  6.13 $ 3,724.700  Millions$ 607.800  Millions
Serina Therapeutics Inc   6.12 $ 23.024  Millions$ 3.762  Millions
Revelation Biosciences Inc   6.11 $ 11.483  Millions$ 1.880  Millions
Spero Therapeutics Inc   6.02 $ 50.774  Millions$ 8.428  Millions

Date modified: 2026-09-08T17:43:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.